Showing 3231-3240 of 5773 results for "".
- Optometry Giving Sight Earns Four-Star Rating From Charity Navigatorhttps://modernod.com/news/optometry-giving-sight-earns-four-star-rating-from-charity-navigator/2482001/Optometry Giving Sight (OGS) has announced that its strong financial health and ongoing accountability and transparency have earned a Four-Star rating from Charity Navigator. This rating designates Optometry Giving Sight as an official “Give with Confidence” charity, indicating t
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- Horus Pharma Strengthens Its International Expansionhttps://modernod.com/news/horus-pharma-strengthens-its-international-expansion/2481996/Horus Pharma, a France-based provider of preservative-free ophthalmology products, announced it is strengthening its international presence with eight distribution agreements covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland, and Bosnia. The deals take
- Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Boardhttps://modernod.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding N
- Ciliatech Releases New Design of Glaucoma Surgical Device CIDhttps://modernod.com/news/ciliatech-releases-new-design-of-glaucoma-surgical-device-cid/2481993/Ciliatech announced the release of a new design of its CID (cilioscleral interpositioning device) following the filing of additional patents strengthening its IP (intellectual property). CID is the unique glaucoma surgical device used in the cilioscleral technique to lower IOP whil
- Corza Medical Opens Ophthalmology Center of Technology and Innovationhttps://modernod.com/news/corza-medical-opens-ophthalmology-center-of-technology-and-innovation/2481992/Corza Medical announced the opening of its new Ophthalmology Center of Technology and Innovation in St. Louis. The state-of-the-art facility is aimed at advancing the development of next-generation devices for ophthalmic surgeries and other eye treatments. With an approximate footp
- RetinAI Joins Ryan Initiative for Macular Research AMD Consortiumhttps://modernod.com/news/retinai-joins-ryan-initiative-for-macular-research-amd-consortium/2481987/RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.</
- Harrow Completes Transfer of the Triesence New Drug Applicationhttps://modernod.com/news/harrow-completes-transfer-of-the-triesence-new-drug-application/2481986/Harrow announced the completion of the transfer to the company of the New Drug Application (NDA) for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. Triesence is a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and
- Ocuphire Pharma Appoints Joseph K. Schachle COOhttps://modernod.com/news/ocuphire-pharma-reports-inducement-grant-for-new-coo/2481985/Ocuphire Pharma announced that the independent members of its Board of Directors approved an equity award under the company’s 2021 Inducement Plan as a material inducement to Joseph K. Schachle in connection with his employment with Ocuphire effective on November 27, 2023. The equity award
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe